Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy
Phase 2
Completed
- Conditions
- Multiple System Atrophy
- Registration Number
- NCT00911365
- Lead Sponsor
- Yonsei University
- Brief Summary
This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- 75 Years Old or Less
- Multiple System Atrophy
- Voluntary Participants
Exclusion Criteria
- Doubted dementia (MMSE < 24)
- Severe febrile condition
- Serum SGOT/SGPT three times above
- Malignant mass
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Scores on unified MSA rating scale one month The statistical difference between scores before and after autologous mesenchymal stem cells treatment of unified MSA rating scale will be measured every month and every year using paired t-test.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie autologous MSC therapy efficacy in MSA neuroprotection?
How does autologous MSC treatment compare to standard care in MSA functional outcomes?
Which biomarkers predict response to MSC therapy in MSA subtypes like MSA-C or MSA-P?
What are the safety profiles and adverse event management strategies for autologous MSCs in MSA?
What combination therapies or alternative stem cell approaches are being explored for MSA alongside Yonsei's trial?
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital🇰🇷Seoul, Korea, Republic of